Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6393111 | 0.94 | ALDH1A1 (0.74) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL15899119 | 0.92 | ALDH1A1 (0.71) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL5799550 | 0.92 | ALDH1A1 (0.71) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL505791 | 0.88 | ALDH1A1 (0.69) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL1820762 | 0.87 | ALDH1A1 (1.00) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL1582969 | 0.87 | ALDH1A1 (0.91) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL9439700 | 0.87 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL8970657 | 0.85 | ALDH1A1 (0.87) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL8970703 | 0.85 | ALDH1A1 (0.87) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 | |
| SCHEMBL4001371 | 0.85 | ALDH1A1 (0.87) | ALDH1A1CYP3A4CYP2C9CYP2C19CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104945358-A | Method for synthesizing allylsuccinic anhydride | SHANGHAI DONGYUE BIOCHEM CO LTD | 2015-09-30 | — | — | CN | claimed |
| CN-106414525-B | Photocurable resin composition | 电化株式会社 | 2021-09-21 | — | — | CN | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9636330-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3002285-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| CN-104945358-A | Method for synthesizing allylsuccinic anhydride | SHANGHAI DONGYUE BIOCHEM CO LTD | 2015-09-30 | — | — | CN | disclosed |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | ALDH1A1 3526/4885CYP3A4 2213/4885CYP2C9 2399/4885 |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ALDH1A1 1022/4885CYP3A4 1471/4885CYP2C9 754/4885 |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ALDH1A1 1081/4885CYP3A4 1620/4885CYP2C9 812/4885 |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ALDH1A1 1081/4885CYP3A4 1620/4885CYP2C9 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.